A special episode from our sister podcast, What’s News.
The U.S. and Israel launched a wave of strikes against Iran, targeting its leadership and military assets in an attack that risked sparking a wider conflict in one of the most economically sensitive regions in the world.
A viral blog post by a relatively unknown research firm sent the stock market on a wild ride this week. The post by Citrini Research tapped into a new strain of fears about artificial intelligence, painting a dark portrait of a future in which technological change leads to mass white collar unemployment. WSJ’s David Uberti explains why Wall Street is jumpy about the prospects for AI. Ryan Knutson hosts.
Newell Brands, the Atlanta-based maker of dozens of household brands including Rubbermaid, Coleman and Yankee Candle, paid more than $170 million in tariffs last year. Newell’s CEO Chris Peterson tells Jessica Mendoza that those tariffs hurt business and the company is considering requesting a refund. He also talks about plans to bring more manufacturing to America. One of its brands, Sharpie, is now almost completely made in the United States. But making that happen wasn’t easy.
President Trump has spent much of the past year trying to pump up international investment in U.S. factories. He's promised to bring back jobs that have moved overseas. WSJ’s Gavin Bade investigates a Chinese automotive glass plant in the Ohio heartland and explores the risks when America’s biggest rival sets up shop. Jessica Mendoza hosts.
Anthropic is feuding with the U.S. military, despite their massive $200 million contract. The company says that its AI model, Claude, cannot be used for weapons development or surveillance. The Pentagon is pushing back against those limitations. WSJ's Amrith Ramkumar joins Jessica Mendoza to explain why the Department of Defense is now threatening to label Anthropic a supply chain risk.
In a 6-3 decision, the Supreme Court ruled that President Trump’s global tariffs are illegal. It is the first time the Supreme Court has definitively struck down one of Trump’s second-term policies, saying the president went too far in enacting his most sweeping tariffs without clear authorization from Congress. WSJ’s Gavin Bade unpacks the ruling and discusses Trump’s next steps. Ryan Knutson hosts.
Yesterday, Meta CEO Mark Zuckerberg testified in a first-of-its-kind trial with one central question: Are social media platforms causing mental health disorders among young people? The plaintiff argues that platforms like Instagram are designed to keep children addicted, potentially bypassing long-standing legal shields that have protected tech companies in the past. WSJ’s Meghan Bobrowsky takes us inside the courtroom for Mark Zuckerberg’s testimony and explains why this trial could impact thousands of other cases. Ryan Knutson hosts. Further Listening: - The Battle Within Meta Over Chatbot Safety - “The Facebook Files’ from The Journal. Sign up for WSJ’s free What’s News newsletter.
The Food and Drug Administration agreed to begin a review of biotech company Moderna’s application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ’s Liz Essley Whyte takes us inside the FDA’s unexpected reversals and explores what’s next for the mRNA flu vaccine. Jessica Mendoza hosts.
Prediction markets like Polymarket and Kalshi are booming, but they’re facing questions about users betting on information that is not publicly available, from Super Bowl performances to geopolitical crises. Advocates for the platforms say they are "truth machines" but critics say they’re a new vehicle for insider trading. WSJ’s Caitlin Ostroff explains how users are making fortunes, and why regulators are starting to take notice. Ryan Knutson hosts.